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Background
HIV-1 diversity is considered a major hurdle for the suc-
cessful design of a vaccine as well as for the development
of reagents to assess vaccine efficacy. The aim of the
present study is to evaluate the variability of Gag and Nef
immunodominant regions previously described in HIV
positive Brazilian individuals infected with B and F1 sub-
types.
Methods
A total of 51 Gag (30 B; 21 F1) and 86 Nef (50 B; 36 F1)
sequences were analyzed. Amino acid distances were cal-
culated for the targeted immunodominant and non-
immunodominant regions using JTT matrix model as
implemented in MEGA program.
Results
No simple association was observed between the fre-
quency of immune recognition (immune selective pres-
sure) and the amino acid diversity in Gag and Nef
proteins HIV positive Brazilian individuals infected with B
and F1 subtypes. The mean amino acid diversity of Nef
immunodominant regions (first region: 12,1% on B and
10,9% on F1; second region: 10,1% on B and 11,1% on
F1) was lower than the diversity of non-immunodomi-
nant region (13,2% on B and 12,1% on F1). Gag immun-
odominant regions (first region: 8,2% on B and 12,3% on
F1; second region: 12,7% on B and 18,3% on F1) dis-
played both lower and higher diversity when compared
with non-immunodominant regions (first region: 14,1%
on B and 7% on F1; second region: 14% on B and 19% on
F1).
Conclusion
These results reveals that a higher immune selective pres-
sure is not always associated with higher levels of amino
acid diversity in immunodominant Gag and Nef regions,
suggesting that these regions could be subject to higher
purifying selection pressure than other non-immunodo-
minant regions.
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